AGT and neoplasm: It is noteworthy that CX3CL1 (also called fractalkine) was down-modulated irrespective of patient outcome, whereas AGT and ATP1A2 were down-modulated only compared to primary tumor cells from patients alive at 5-year follow-up (Figures S2, S3, S5, S6), which suggests that they may represent novel surrogate markers of tumor aggressiveness.